8-K Announcements
6Material company update
Apr 2, 2026·SEC
Material company update
Feb 23, 2026·SEC
Material company update
Dec 29, 2025·SEC
Silo Pharma, Inc.(SILO)Earnings, Financials & Key Ratios
SILO•NASDAQ
Price updated Jun 19, 2026
AboutSilo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.Show more
- Revenue$72K
- EBITDA-$4M+9.2%
- Net Income-$4M+3.8%
- EPS (Diluted)-7.50+58.0%
- Gross Margin-1128.89%-1328.4%
- EBITDA Margin-5921.09%+9.2%
- Operating Margin-5936.95%+9.0%
- Net Margin-5863.5%+3.8%
- ROE-74.56%+4.9%
SILO Key Insights
Silo Pharma, Inc. (SILO) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 0.5x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when SILO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SILO Price & Volume
Silo Pharma, Inc. (SILO) stock price & volume — 10-year historical chart
Loading chart...
SILO Growth Metrics
Silo Pharma, Inc. (SILO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years0%
TTM0%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-4.77%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM56.85%
Return on Capital
10 Years-79.28%
5 Years-53.32%
3 Years-61.24%
Last Year-67.35%
SILO Recent Earnings
Silo Pharma, Inc. (SILO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 1/12 qtrs (25%)●Beat Revenue 4/12 qtrs (100%)
Q2 2026Latest
May 14, 2026Metric
Actual
Est
EPS
$0.12+62.5%
$0.32
Rev
$18,026+0.1%
$18,000
Q2 2026
Mar 27, 2026Metric
Actual
Est
EPS
$0.07
—
Rev
$18,026
—
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$0.12
—
Rev
$18,025
—
Q3 2025
Aug 13, 2025Metric
Actual
Est
EPS
$0.19
—
Rev
$18,025
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 14, 2026 | $0.12vs $0.32+62.5% | $18,026vs $18,000+0.1% |
| Q2 2026 | Mar 27, 2026 | $0.07 | $18,026 |
| Q4 2025 | Nov 13, 2025 | $0.12 | $18,025 |
| Q3 2025 | Aug 13, 2025 | $0.19 | $18,025 |
Based on last 12 quarters of dataView full earnings history →
SILO Peer Comparison
Silo Pharma, Inc. (SILO) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CMPS | 1.2B | 12.53 | -4.07 | -151.02% | ||||
 MNMD | 2.04B | 20.69 | -10.04 | -102.48% | ||||
 ATAI | 1.49B | 4.06 | -1.40 | 12.28% | -190.19% | -366.21% | 0.01 | |
 CYBN | 303.86M | 6.09 | -13.66 | -81% | ||||
 PSTV | 10.16M | 4.20 | -0.58 | -10.49% | -230.24% | -198.48% | 0.21 | |
 ENVB | 764.17K | 1.28 | -0.04 | -220.99% | ||||
 MGRX | 3.33M | 0.33 | -0.16 | -25.96% | -46.33% | -120.72% | 0.02 | |
 DRUG | 470.81M | 60.66 | -48.07 | -20.72% | 0.00 |
Compare SILO vs Peers
Silo Pharma, Inc. (SILO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SILO Income Statement
Silo Pharma, Inc. (SILO) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 847.41K | 0 | 40.57K | 0 | 71.26K | 72.1K | 72.1K | 72.1K | 72.1K | 72.1K |
Revenue Growth % | 226.58% | -100% | - | -100% | - | 1.18% | 0% | 0% | 0% | 0% |
Cost of Goods Sold | 0 | 17.55K | 27.39K | 0 | 5K | 5.84K | 5.84K | 5.84K | 886.06K | 309.09K |
COGS % of Revenue | - | - | 67.51% | - | 7.02% | 8.1% | 8.1% | 8.1% | 1228.89% | - |
Gross Profit | 847.41K▲ 0% | -17.55K▼ 102.1% | 13.18K▲ 175.1% | 0▼ 100.0% | 66.26K▲ 0% | 66.26K▲ 0.0% | 66.26K▲ 0.0% | 66.26K▲ 0.0% | -813.96K▼ 1328.4% | -236.99K▲ 0% |
Gross Margin % | 100% | - | 32.49% | - | 92.98% | 91.9% | 91.9% | 91.9% | -1128.89% | -328.69% |
Gross Profit Growth % | 226.58% | -102.07% | 175.11% | -100% | - | 0.01% | 0% | 0% | -1328.35% | - |
Operating Expenses | 490.87K | 459.83K | 943.59K | 2.2M | 2.81M | 3.69M | 3.92M | 4.77M | 3.47M | 4.54M |
OpEx % of Revenue | 57.93% | - | 2325.88% | - | 3943.93% | 5123.19% | 5439.32% | 6618.34% | 4808.06% | - |
Selling, General & Admin | 313.37K | 459.83K | 864.18K | 2.18M | 2.27M | 2.43M | 3.08M | 2.4M | 2.15M | 1.96M |
SG&A % of Revenue | 36.98% | - | 2130.15% | - | 3178.59% | 3366.74% | 4267.24% | 3333.89% | 2978.61% | - |
Research & Development | 0 | 0 | 63.47K | 26.25K | 693.91K | 1.29M | 845.09K | 2.37M | 2.16M | 2.58M |
R&D % of Revenue | - | - | 156.44% | - | 973.72% | 1784.19% | 1172.08% | 3284.45% | 2996.91% | - |
Other Operating Expenses | 177.5K | 314.61K | 15.94K | 0 | -148.5K | -20K | 0 | 0 | -841.76K | 0 |
Operating Income | -470.39K▲ 0% | -594.24K▼ 26.3% | -930.4K▼ 56.6% | -2.2M▼ 136.6% | -2.74M▼ 24.6% | -3.63M▼ 32.2% | -3.86M▼ 6.3% | -4.71M▼ 22.0% | -4.28M▲ 9.0% | -4.78M▲ 0% |
Operating Margin % | -55.51% | - | -2293.38% | - | -3850.95% | -5031.28% | -5347.41% | -6526.44% | -5936.95% | -6631.16% |
Operating Income Growth % | -19.49% | -26.33% | -56.57% | -136.64% | -24.65% | -32.19% | -6.28% | -22.05% | 9.03% | - |
EBITDA | 356.54K | -576.69K | -950.37K | -2.4M | 4.19M | -3.91M | -3.63M | -4.7M | -4.27M | -4.77M |
EBITDA Margin % | 42.07% | - | -2342.59% | - | 5872.56% | -5416.2% | -5029.28% | -6517.86% | -5921.09% | -6615.51% |
EBITDA Growth % | 9.48% | -261.75% | -64.8% | -152.22% | 274.59% | -193.31% | 7.14% | -29.6% | 9.16% | 2.7% |
D&A (Non-Cash Add-back) | 0 | 17.55K | 0 | 0 | 0 | 0 | 0 | 6.18K | 11.44K | 11.29K |
EBIT | 356.54K | -969.46K | -950.37K | -2.4M | 4.19M | -3.91M | -3.63M | -4.39M | -4.19M | -4.8M |
Net Interest Income | 0 | 0 | -50.73K | -257.72K | -1.83K | 70.44K | 393.66K | 328.08K | 156.61K | 132.19K |
Interest Income | 20.48K | 4.22K | 12.2K | 11.54K | 1.21K | 72.64K | 398.53K | 333.17K | 193.91K | 170.8K |
Interest Expense | 0 | 0 | 62.93K | 269.27K | 3.04K | 2.2K | 4.87K | 5.08K | 37.3K | 38.61K |
Other Income/Expense | 826.92K | -375.22K | -82.89K | -464.55K | 6.93M | -279.73K | 224.51K | 312.81K | 52.96K | -62.18K |
Pretax Income | 356.54K▲ 0% | -969.46K▼ 371.9% | -1.01M▼ 4.5% | -2.67M▼ 163.1% | 4.18M▲ 256.8% | -3.91M▼ 193.4% | -3.63M▲ 7.1% | -4.39M▼ 21.0% | -4.23M▲ 3.8% | -4.84M▲ 0% |
Pretax Margin % | 42.07% | - | -2497.71% | - | 5868.3% | -5419.25% | -5036.04% | -6092.59% | -5863.5% | -6717.4% |
Income Tax | 0 | 0 | 0 | 0 | 24.88K | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0.59% | 0% | 0% | 0% | 0% | 0% |
Net Income | 356.54K▲ 0% | -969.46K▼ 371.9% | -1.01M▼ 4.5% | -3.04M▼ 199.8% | 3.9M▲ 228.5% | -3.91M▼ 200.1% | -3.7M▲ 5.3% | -4.39M▼ 18.7% | -4.23M▲ 3.8% | -4.84M▲ 0% |
Net Margin % | 42.07% | - | -2497.71% | - | 5477.86% | -5420.86% | -5132.57% | -6092.59% | -5863.5% | -6717.4% |
Net Income Growth % | 132.03% | -371.91% | -4.52% | -199.77% | 228.52% | -200.12% | 5.32% | -18.7% | 3.76% | -4.77% |
Net Income (Continuing) | 356.54K | -969.46K | -1.01M | -2.67M | 4.16M | -3.91M | -3.63M | -4.39M | -4.23M | -4.84M |
Discontinued Operations | 0 | 0 | 0 | -371.25K | -253.37K | -1.16K | -69.6K | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 7.50▲ 0% | -14.85▼ 298.0% | -18.60▼ 25.3% | -35.25▼ 89.5% | 19.50▲ 155.3% | -25.65▼ 231.5% | -18.00▲ 29.8% | -17.85▲ 0.8% | -7.50▲ 58.0% | -5.30▲ 0% |
EPS Growth % | 145.05% | -298% | -25.25% | -89.52% | 155.32% | -231.54% | 29.82% | 0.83% | 57.98% | 56.85% |
EPS (Basic) | 7.50 | -14.85 | -18.60 | -35.25 | 19.80 | -25.65 | -18.00 | -17.85 | -7.50 | - |
Diluted Shares Outstanding | 69.44K | 65.47K | 56.15K | 87.94K | 127.9K | 152.28K | 205.32K | 245.36K | 558.82K | 913.95K |
Basic Shares Outstanding | 66.78K | 65.47K | 56.15K | 87.94K | 126.49K | 152.28K | 205.32K | 245.36K | 558.82K | 913.95K |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
SILO Balance Sheet
Silo Pharma, Inc. (SILO) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 1.64M | 625.98K | 493.85K | 1.43M | 10.4M | 11.57M | 7.68M | 7.11M | 7.39M | 6.8M |
Cash & Short-Term Investments | 294.59K | 564.97K | 121.15K | 1.13M | 10.26M | 11.37M | 7.67M | 7.08M | 6.86M | 6.27M |
Cash Only | 294.59K | 336.68K | 111.75K | 1.13M | 9.84M | 11.37M | 3.52M | 3.91M | 4.75M | 3.9M |
Short-Term Investments | 0 | 228.29K | 9.39K | 200 | 420K | 3.12K | 4.14M | 3.17M | 2.11M | 2.37M |
Accounts Receivable | 0 | 0 | 200K | 23.5K | 0 | 66.01K | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | 1.8K | - | - | 334.16 | - | - | - | - |
Inventory | 0 | 26.97K | 156.37K | 33.48K | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | 560.98 | 2.08K | - | - | - | - | - | - | - |
Other Current Assets | 1.35M | 0 | 0 | 0 | 145.32K | 0 | 15.97K | 30.96K | 528.96K | 529.39K |
Total Non-Current Assets | 1.32M | 229.44K | 0 | 0 | 87.87K | 70.82K | 64.98K | 300.36K | 217.38K | 214.44K |
Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | - |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 29.44K | 0 | 0 | 0 | 0 | 0 | 241.22K | 217.38K | 214.44K |
Long-Term Investments | 1.32M | 200K | 0 | 0 | 61.21K | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 26.66K | 70.82K | 64.98K | 59.15K | 0 | 0 |
Total Assets | 1.64M▲ 0% | 855.42K▼ 47.9% | 493.85K▼ 42.3% | 1.43M▲ 188.9% | 10.49M▲ 635.3% | 11.64M▲ 11.0% | 7.75M▼ 33.5% | 7.41M▼ 4.3% | 7.61M▲ 2.6% | 7.02M▲ 0% |
Asset Turnover | 0.52x | - | 0.08x | - | 0.01x | 0.01x | 0.01x | 0.01x | 0.01x | 0.01x |
Asset Growth % | 26.3% | -47.88% | -42.27% | 188.89% | 635.29% | 10.99% | -33.47% | -4.32% | 2.61% | -21.15% |
Total Current Liabilities | 38.34K | 47.98K | 116.74K | 141.72K | 490.04K | 436.32K | 775.59K | 1.66M | 650.18K | 704.85K |
Accounts Payable | 38.34K | 25.63K | 54.86K | 127.07K | 417.94K | 364.22K | 703.49K | 1.58M | 578.08K | 632.74K |
Days Payables Outstanding | - | 533.07 | 731.17 | - | 30.49K | 22.77K | 43.98K | 99.03K | 238.13 | 833.95 |
Short-Term Debt | 0 | 22.34K | 61.88K | 14.65K | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 0 | -25.63K | -116.74K | 0 | 72.1K | 72.1K | 72.1K | 72.1K | 72.1K | 288.41K |
Other Current Liabilities | 0 | 0 | 116.74K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Current Ratio | 42.81x | 13.05x | 4.23x | 10.07x | 21.23x | 26.52x | 9.90x | 4.29x | 11.36x | 9.65x |
Quick Ratio | 42.81x | 12.49x | 2.89x | 9.83x | 21.23x | 26.52x | 9.90x | 4.29x | 11.36x | 9.65x |
Cash Conversion Cycle | - | - | 3.15K | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 400K | 400K | 400K | 4.25K | 937.88K | 865.78K | 793.68K | 721.58K | 649.48K | 631.45K |
Long-Term Debt | 0 | 0 | 0 | 4.25K | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 400K | 400K | 400K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 438.34K | 447.98K | 516.74K | 145.97K | 1.43M | 1.3M | 1.57M | 2.38M | 1.3M | 1.34M |
Total Debt | 0 | 22.34K | 61.88K | 18.9K | 0 | 0 | 0 | 0 | 0 | 0 |
Net Debt | -294.59K | -314.33K | -49.88K | -1.11M | -9.84M | -11.37M | -3.52M | -3.91M | -4.75M | -3.9M |
Debt / Equity | - | 0.05x | - | 0.01x | - | - | - | - | - | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.00x |
Net Debt / EBITDA | -0.83x | - | - | - | -2.35x | - | - | - | - | 0.82x |
Interest Coverage | - | - | -15.10x | -8.90x | 1378.47x | -1775.89x | -744.76x | -863.06x | -112.34x | -124.45x |
Total Equity | 1.2M▲ 0% | 407.44K▼ 66.1% | -22.89K▼ 105.6% | 1.28M▲ 5694.5% | 9.06M▲ 607.6% | 10.34M▲ 14.1% | 6.18M▼ 40.3% | 5.03M▼ 18.5% | 6.31M▲ 25.3% | 5.68M▲ 0% |
Equity Growth % | 42.12% | -66.13% | -105.62% | 5694.51% | 607.61% | 14.11% | -40.27% | -18.5% | 25.25% | 23.29% |
Book Value per Share | 17.32 | 6.22 | -0.41 | 14.56 | 70.86 | 67.91 | 30.08 | 20.52 | 11.28 | 6.22 |
Total Shareholders' Equity | 1.2M | 407.44K | -22.89K | 1.28M | 9.06M | 10.34M | 6.18M | 5.03M | 6.31M | 5.68M |
Common Stock | 5.01K | 2.34K | 2.36K | 8.51K | 9.86K | 316 | 316 | 449 | 1.33K | 1.63K |
Retained Earnings | -470.39K | -1.64M | -2.66M | -5.76M | -3.26M | -7.17M | -10.87M | -15.26M | -19.49M | -21.14M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | -471.12K | 0 | 0 | 0 |
Accumulated OCI | -1.12M | -400K | -400K | 0 | 0 | 0 | -6.23K | 2.42K | 5.83K | 8.72K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SILO Cash Flow Statement
Silo Pharma, Inc. (SILO) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -284.62K | 272.64K | -794.32K | -1.16M | -2.28M | -3.5M | -3.22M | -3.83M | -4.66M | -3.84M |
Operating CF Margin % | -33.59% | - | -1957.96% | - | -3196.59% | -4850.94% | -4472.13% | -5317.35% | -6464.92% | - |
Operating CF Growth % | -98.26% | 195.79% | -391.35% | -45.66% | -96.89% | -53.54% | 7.81% | -18.9% | -21.58% | 18.21% |
Net Income | 356.54K | -969.46K | -1.01M | -3.04M | 4.16M | -3.91M | -3.7M | -4.39M | -4.23M | -4.84M |
Depreciation & Amortization | 0 | 17.55K | 0 | 0 | 0 | 0 | 0 | 6.18K | 11.44K | 5.72K |
Stock-Based Compensation | 0 | 0 | 177.96K | 1.19M | 0 | 156.05K | 14.13K | 0 | 117.02K | 99.58K |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -606.45K | 1.24M | 123.47K | 763.26K | -7.14M | 330.17K | 162.78K | 1.02K | 621.87K | -705.47K |
Working Capital Changes | -34.71K | -16.8K | -82.46K | -72.14K | 704.75K | -75.29K | 299.27K | 551.76K | -1.18M | -635.84K |
Change in Receivables | -20.36K | 0 | 0 | 0 | -1.21K | -4.8K | -3.59K | 0 | 0 | 0 |
Change in Inventory | 0 | -26.97K | -129.39K | -15.06K | -24.96K | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -14.76K | -12.71K | 0 | 0 | 0 | -53.72K | 339.27K | 0 | 0 | 0 |
Cash from Investing | 157.57K | -250K | 186.74K | 39K | 7.19M | 86.71K | -4.15M | 973.78K | 644.02K | -250.92K |
Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CapEx % of Revenue | - | - | - | - | 0.01% | - | - | - | - | 0% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | -977.5K | 0 | 39K | 172K | 20K | 0 | 0 | -574.92K | 759.54K |
Cash from Financing | 0 | 19.45K | 382.66K | 2.13M | 3.79M | 4.94M | -471.12K | 3.24M | 4.86M | 4.86M |
Debt Issued (Net) | 0 | -2.18K | 272.66K | 18.9K | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 0 | 21.63K | 110K | 2.12M | 3.79M | 4.94M | -471.12K | 3.24M | 4.86M | 4.86M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | -2.87K | 0 | 0 | 0 | 0 | -471.12K | -173.11K | 0 | 0 |
Other Financing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 |
Net Change in Cash | -284.62K▲ 0% | 42.09K▲ 114.8% | -224.93K▼ 634.4% | 1.02M▲ 552.0% | 8.71M▲ 756.6% | 1.53M▼ 82.4% | -7.84M▼ 612.6% | 381.49K▲ 104.9% | 842.9K▲ 120.9% | 765.63K▲ 0% |
Free Cash Flow | -284.62K▲ 0% | 272.64K▲ 195.8% | -794.32K▼ 391.3% | -1.16M▼ 45.7% | -2.28M▼ 96.9% | -3.5M▼ 53.5% | -3.22M▲ 7.8% | -3.83M▼ 18.9% | -4.66M▼ 21.6% | -3.84M▲ 0% |
FCF Margin % | -33.59% | - | -1957.96% | - | -3196.59% | -4850.94% | -4472.13% | -5317.35% | -6464.92% | -5330.86% |
FCF Growth % | -98.26% | 195.79% | -391.35% | -45.66% | -96.89% | -53.54% | 7.81% | -18.9% | -21.58% | 17.09% |
FCF per Share | -4.10 | 4.16 | -14.15 | -13.16 | -17.81 | -22.97 | -15.70 | -15.63 | -8.34 | -4.21 |
FCF Conversion (FCF/Net Income) | -0.80x | -0.28x | 0.78x | 0.38x | -0.58x | 0.89x | 0.87x | 0.87x | 1.10x | 0.79x |
Interest Paid | 0 | 0 | 0 | 224 | 0 | 2.2K | 4.87K | 5.08K | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 25.16K | 0 | 0 | 0 | 0 |
SILO Key Ratios
Silo Pharma, Inc. (SILO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 34.79% | -120.39% | -527% | -482.99% | 75.49% | -40.29% | -44.81% | -78.37% | -74.56% | -88.41% |
Return on Invested Capital (ROIC) | -60.01% | -89% | -6862.05% | -3355.02% | - | - | -355.62% | -186.68% | -239.12% | -286.26% |
Gross Margin | 100% | - | 32.49% | - | 92.98% | 91.9% | 91.9% | 91.9% | -1128.89% | -328.69% |
Net Margin | 42.07% | - | -2497.71% | - | 5477.86% | -5420.86% | -5132.57% | -6092.59% | -5863.5% | -6717.4% |
Debt / Equity | - | 0.05x | - | 0.01x | - | - | - | - | - | 0.00x |
Interest Coverage | - | - | -15.10x | -8.90x | 1378.47x | -1775.89x | -744.76x | -863.06x | -112.34x | -124.45x |
FCF Conversion | -0.80x | -0.28x | 0.78x | 0.38x | -0.58x | 0.89x | 0.87x | 0.87x | 1.10x | 0.79x |
Revenue Growth | 226.58% | -100% | - | -100% | - | 1.18% | 0% | 0% | 0% | 0% |
Related:SILO Dividend History·SILO Revenue History·SILO Price History·SILO P/E History·SILO Financial Ratios·SILO Institutional Holders
SILO SEC Filings & Documents
Silo Pharma, Inc. (SILO) SEC filings — annual & quarterly reports (10-K, 10-Q)
SILO Frequently Asked Questions
Silo Pharma, Inc. (SILO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Silo Pharma, Inc. (SILO) reported $0.1M in revenue for fiscal year 2025.
Silo Pharma, Inc. (SILO) grew revenue by 0.0% over the past year. Growth has been modest.
Silo Pharma, Inc. (SILO) reported a net loss of $4.8M for fiscal year 2025.
Dividend & Returns
Silo Pharma, Inc. (SILO) has a return on equity (ROE) of -74.6%. Negative ROE indicates the company is unprofitable.
Silo Pharma, Inc. (SILO) had negative free cash flow of $3.8M in fiscal year 2025, likely due to heavy capital investments.